Cargando…

3550 Understanding Racial Disparities in Hepatocellular Carcinoma Treatments and Outcomes

OBJECTIVES/SPECIFIC AIMS: Black patients with hepatocellular carcinoma (HCC) receive fewer curative therapies and have higher mortality than other groups. Reducing this disparity will require an in-depth understanding of patient comorbidities, tumor characteristics, and social determinants of health...

Descripción completa

Detalles Bibliográficos
Autores principales: Nephew, Lauren Devore, Rawl, Susan, Chalasani, Naga
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6799188/
http://dx.doi.org/10.1017/cts.2019.225
_version_ 1783460229644550144
author Nephew, Lauren Devore
Rawl, Susan
Chalasani, Naga
author_facet Nephew, Lauren Devore
Rawl, Susan
Chalasani, Naga
author_sort Nephew, Lauren Devore
collection PubMed
description OBJECTIVES/SPECIFIC AIMS: Black patients with hepatocellular carcinoma (HCC) receive fewer curative therapies and have higher mortality than other groups. Reducing this disparity will require an in-depth understanding of patient comorbidities, tumor characteristics, and social determinants of health. Our objectives are to a) perform a multi-center retrospective cohort study of black and white patients diagnosed with HCC in the Indianapolis area. b) prospectively enroll black and white patients with HCC to collect clinical characteristics as well as data on the social determinants of health. METHODS/STUDY POPULATION: A retrospective chart review of patients with a diagnosis of HCC from 2010-2017 from five area Indianapolis hospitals will be performed. Demographics, comorbidities, liver disease severity, and tumor characteristics will be collected using the Indiana Network for Patient Care database and compared between black and white patients. Concomitantly, a prospective cohort of black and white patients will be enrolled and surveyed to collect data on socioeconomic status and income adequacy, literacy, functional status, substance abuse history, social support, activation, and adherence. The primary outcomes are the receipt of curative therapies for HCC including liver transplantation, resection or ablation. The secondary outcome is mortality. Multivariable logistic regression models will be used to explore disparities seen in the primary and secondary outcomes. RESULTS/ANTICIPATED RESULTS: These preliminary results include Indiana University Hospital (IUH) findings; a multicenter analysis is underway. The IUH cohort included 1,032 (86%) white and 164 (14%) black patients. Black and white patients had similar Model for End-Stage Liver Disease and Child-Pugh scores. There was a trend toward larger tumor size (5.3 cm vs. 4.7 cm; P = 0.05) in black patients; however, Barcelona Clinic Liver Cancer staging and Milan criteria were similar. Black patients were less likely to undergo liver transplantation than white patients—a disparity that was not attenuated (odds ratio [OR], 0.43; 95% confidence interval [CI]: 0.21-0.90) on multivariable analysis. Substance abuse was more frequently cited as the reason black patients within Milan criteria failed to undergo transplantation than white patients. Survival was similar between the two groups. DISCUSSION/SIGNIFICANCE OF IMPACT: Racial differences in patient and tumor characteristics were small in our single center analysis and did not explain the disparity in liver transplantation. This analysis however only reflects 25% of patients diagnosed with HCC in the Indianapolis metropolitan, highlighting the need for a multicenter study. Higher rates of substance abuse in black patients within Milan criteria who failed to undergo transplantation suggest social factors contribute to this disparity and highlight the need for a prospective study that can explore these and other social factors.
format Online
Article
Text
id pubmed-6799188
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-67991882019-10-28 3550 Understanding Racial Disparities in Hepatocellular Carcinoma Treatments and Outcomes Nephew, Lauren Devore Rawl, Susan Chalasani, Naga J Clin Transl Sci Health Equity & Community Engagement OBJECTIVES/SPECIFIC AIMS: Black patients with hepatocellular carcinoma (HCC) receive fewer curative therapies and have higher mortality than other groups. Reducing this disparity will require an in-depth understanding of patient comorbidities, tumor characteristics, and social determinants of health. Our objectives are to a) perform a multi-center retrospective cohort study of black and white patients diagnosed with HCC in the Indianapolis area. b) prospectively enroll black and white patients with HCC to collect clinical characteristics as well as data on the social determinants of health. METHODS/STUDY POPULATION: A retrospective chart review of patients with a diagnosis of HCC from 2010-2017 from five area Indianapolis hospitals will be performed. Demographics, comorbidities, liver disease severity, and tumor characteristics will be collected using the Indiana Network for Patient Care database and compared between black and white patients. Concomitantly, a prospective cohort of black and white patients will be enrolled and surveyed to collect data on socioeconomic status and income adequacy, literacy, functional status, substance abuse history, social support, activation, and adherence. The primary outcomes are the receipt of curative therapies for HCC including liver transplantation, resection or ablation. The secondary outcome is mortality. Multivariable logistic regression models will be used to explore disparities seen in the primary and secondary outcomes. RESULTS/ANTICIPATED RESULTS: These preliminary results include Indiana University Hospital (IUH) findings; a multicenter analysis is underway. The IUH cohort included 1,032 (86%) white and 164 (14%) black patients. Black and white patients had similar Model for End-Stage Liver Disease and Child-Pugh scores. There was a trend toward larger tumor size (5.3 cm vs. 4.7 cm; P = 0.05) in black patients; however, Barcelona Clinic Liver Cancer staging and Milan criteria were similar. Black patients were less likely to undergo liver transplantation than white patients—a disparity that was not attenuated (odds ratio [OR], 0.43; 95% confidence interval [CI]: 0.21-0.90) on multivariable analysis. Substance abuse was more frequently cited as the reason black patients within Milan criteria failed to undergo transplantation than white patients. Survival was similar between the two groups. DISCUSSION/SIGNIFICANCE OF IMPACT: Racial differences in patient and tumor characteristics were small in our single center analysis and did not explain the disparity in liver transplantation. This analysis however only reflects 25% of patients diagnosed with HCC in the Indianapolis metropolitan, highlighting the need for a multicenter study. Higher rates of substance abuse in black patients within Milan criteria who failed to undergo transplantation suggest social factors contribute to this disparity and highlight the need for a prospective study that can explore these and other social factors. Cambridge University Press 2019-03-27 /pmc/articles/PMC6799188/ http://dx.doi.org/10.1017/cts.2019.225 Text en © The Association for Clinical and Translational Science 2019 http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (http://creativecommons.org/licenses/by-ncnd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is unaltered and is properly cited. The written permission of Cambridge University Press must be obtained for commercial re-use or in order to create a derivative work.
spellingShingle Health Equity & Community Engagement
Nephew, Lauren Devore
Rawl, Susan
Chalasani, Naga
3550 Understanding Racial Disparities in Hepatocellular Carcinoma Treatments and Outcomes
title 3550 Understanding Racial Disparities in Hepatocellular Carcinoma Treatments and Outcomes
title_full 3550 Understanding Racial Disparities in Hepatocellular Carcinoma Treatments and Outcomes
title_fullStr 3550 Understanding Racial Disparities in Hepatocellular Carcinoma Treatments and Outcomes
title_full_unstemmed 3550 Understanding Racial Disparities in Hepatocellular Carcinoma Treatments and Outcomes
title_short 3550 Understanding Racial Disparities in Hepatocellular Carcinoma Treatments and Outcomes
title_sort 3550 understanding racial disparities in hepatocellular carcinoma treatments and outcomes
topic Health Equity & Community Engagement
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6799188/
http://dx.doi.org/10.1017/cts.2019.225
work_keys_str_mv AT nephewlaurendevore 3550understandingracialdisparitiesinhepatocellularcarcinomatreatmentsandoutcomes
AT rawlsusan 3550understandingracialdisparitiesinhepatocellularcarcinomatreatmentsandoutcomes
AT chalasaninaga 3550understandingracialdisparitiesinhepatocellularcarcinomatreatmentsandoutcomes